Longeveron Inc. (LGVN) NASDAQ
0.92
-0.025(-2.66%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.92
-0.025(-2.66%)
Currency In USD
Address
1951 NW 7th Avenue
Miami, FL 33136
United States of America (the)
Phone
305 909 0840
Website
Sector
Healthcare
Industry
Biotechnology
Employees
25
First IPO Date
February 12, 2021
| Name | Title | Pay | Year Born |
| Than Powell | Interim Chief Executive Officer & Director | 0 | 1978 |
| Joshua Michael Hare | Co-Founder, Chief Science Officer & Executive Chairman | 600,622 | 1963 |
| Lisa Locklear | Chief Financial Officer, Executive Vice President & Treasurer | 653,391 | 1961 |
| Paul T. Lehr | General Counsel & Secretary | 748,514 | 1968 |
| Nataliya Agafonova | Chief Medical Officer | 0 | 1969 |
| Brian G Rash | Vice President of Research & Discovery | 0 | N/A |
| Devin Blass | Chief Technology Officer & Senior Vice President of Chemistry, Manufacturing, and Controls | 0 | 1986 |
| Heather Zhou | VP & Corporate Controller | 0 | N/A |
| Jen Dumas | Vice President of Human Resources | 0 | N/A |
| Lisa McClain-Moss | Vice President of Manufacturing | 0 | 1971 |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.